Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Pharmaceuticals Inc.

Division of Sun Pharmaceutical Industries Ltd.

Latest From Ranbaxy Pharmaceuticals Inc.

Sun Sees Urgency To Establish Low Dose Absorica In US

Sun’s key specialty asset Ilumya makes progress, albeit slowly, in the US, while the firm sees ‘short window’ to ensure that Absorica LD gains grip in that market ahead of impending arrival of generic.

Commercial Sales & Earnings

Scrip 100: The Architecture Of A Top Heavy Industry

Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.

Commercial Market Intelligence

Evergreening Gets Trimmed? Product Switching Suits On Namenda, Others Proceeding

New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.

BioPharmaceutical United States

Tit For Tat: A Match For PhRMA Takes Shape To Bat For Indian Generics In U.S.

The Indian Pharmaceutical Alliance seeks to dispel the rising perception that the local generic drug industry has poor manufacturing quality standards. It has joined hands with the newly formed India First Group to push the interests of high-quality generic drug makers and form a Coalition of Affordable Care that will combat lobbies like PhRMA and GIPC.

BioPharmaceutical India
See All

Company Information